Akari Therapeutics AKTX

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+2.05%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Akari Therapeutics (AKTX)
    Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.925

    • Market Cap

      $24.49 Million

    • Price-Earnings Ratio

      Infinity

    • Total Outstanding Shares

      49.52 Billion Shares

    • Total Employees

      12

    • Dividend

      No dividend

    • IPO Date

      December 7, 2012

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      American Depository Receipt Common

    • Headquarters

      22 boston wharf road, Boston, MA, 02210

    • Homepage

      https://www.akaritx.com

    Historical Stock Splits

    If you bought 200 shares of AKTX before September 17, 2015, you'd have 1 share today.
    Execution DateSplit Amount
    August 17, 20231-for-20 (Reverse Split)
    September 17, 20151-for-10 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$-14.84 Million
    Net Cash Flow, Continuing$-2,000
    Net Cash Flow From Operating Activities$-14.84 Million
    Net Cash Flow From Investing Activities, Continuing$2.49 Million
    Net Cash Flow$-1,000
    Net Cash Flow From Financing Activities, Continuing$12.35 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Diluted Earnings Per Share$0
    Net Income/Loss$-20.16 Million
    Selling, General, and Administrative Expenses$9.20 Million
    Basic Average Shares$40.20 Billion
    Basic Earnings Per Share$0
    Diluted Average Shares$40.20 Billion

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss Attributable To Parent$-97,000
    Comprehensive Income/Loss$-20.25 Million
    Comprehensive Income/Loss Attributable To Parent$-20.25 Million
    Other Comprehensive Income/Loss$-20.25 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Prepaid Expenses$396,000
    Other Current Liabilities$4.65 Million
    Noncurrent Liabilities$0
    Noncurrent Assets$0
    Other Current Assets$2.34 Million
    Liabilities$9.43 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AKTX from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.